Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesTruscreen Group Ltd

Truscreen Group Ltd

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
0.007 AUD -0.00 ( 12.50%)
Last update at 2026-11-12T03:25:00Z
VOLUME
1048896
Market Cap
9.43M

Momentum Score

…

TruScreen Group Limited, together with its subsidiaries, develops, manufacture, and sale of cancer detection devices and systems in Mexico, China, Central Asia, Vietnam, Zimbabwe, Indonesia, India, and the Middle East/North Africa. It offers TruScreen cervical cancer screening device, a medical device for identifying and detecting the presence of precancerous and cancerous tissue on the cervix in real time. The company was formerly known as TruScreen Limited and changed its name to TruScreen Group Limited in August 2020. TruScreen Group Limited was incorporated in 2013 and is headquartered in Auckland, New Zealand.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.01
Low
0.01
High
52 Week Price Range
0.01
Low
0.03
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Truscreen Group Ltd develops and commercializes a non-invasive cervical screening device to detect precancerous abnormalities. Long-term growth may be supported by regulatory approvals, expanded distribution in emerging markets and recurring consumables and service revenue. Investors may find exposure to a niche diagnostic technology that appears positioned to address screening gaps in low-resource settings.
Material risks include regulatory and reimbursement hurdles, competition from established HPV and cytology testing, limited commercial traction and financing and execution risk typical of small medical-device companies.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.01
Dividend Yield
-
Revenue TTM
2.82M
Revenue Per Share
0.00
Gross Profit TTM
1.16M
Debt / Equity
0.08
ROE
-125.37%
Net Debt
-1.27M
ROCE
-104.36%
Diluted EPS TTM
-

Insight Announcement

View All

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -2.81M -2.24M -2.05M -2.40M -7.89M
Net income -2.27M -2.24M -2.05M -2.40M -7.89M
Selling general administrative - 1.37M 1.29M 1.41M 1.54M
Selling and marketing expenses - 0.63M 0.88M 0.72M 0.71M
Gross profit 0.03M 0.52M 1.16M 0.46M 0.52M
Reconciled depreciation - - - - 0.59M
Ebit -2.80M - -4.40M -2.94M -8.87M
Ebitda -2.66M -2.23M -2.55M -2.94M -8.27M
Depreciation and amortization 0.14M - 1.85M 0.43M 0.59M
Operating income -2.80M -2.15M -1.85M -2.94M -8.87M
Other operating expenses 5.26M 4.33M 4.45M 4.60M 10.55M
Interest expense 0.01M 0.02M - - 0.00M
Tax provision - 0.00M 0.00M 0.00M 0.00M
Interest income - 0.00M 0.00M 0.00M 0.00M
Net interest income - -0.01M 0.00M 0.00M 0.00M
Income tax expense -0.54M -0.36M -1.85M -0.44M -0.00M
Total revenue 2.45M 1.71M 2.60M 1.66M 1.68M
Total operating expenses 2.83M 3.14M 3.02M 3.40M 9.39M
Cost of revenue 2.43M 1.20M 1.44M 1.20M 1.16M
Total other income expense net -0.01M -0.09M -0.20M 0.54M 0.97M
Net income from continuing ops - -2.24M -2.05M -2.40M -7.89M
Net income applicable to common shares - - - -2.40M -7.89M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 3.78M 1.85M 4.03M 3.47M 4.39M
Other current assets 0.23M - 0.27M 0.03M 0.04M
Total liab 1.17M 0.84M 0.80M 0.93M 0.99M
Total stockholder equity 2.60M 1.01M 3.23M 2.54M 3.40M
Other current liab 0.11M - 0.12M 0.09M 0.14M
Common stock 42.74M - 38.71M 36.10M 34.55M
Capital stock - 38.77M 38.71M 36.10M 34.55M
Retained earnings -39.96M -37.47M -35.37M -33.32M -31.22M
Other liab - - - 0.04M 0.04M
Cash 1.47M 0.37M 2.73M 2.16M 2.80M
Total current liabilities 1.09M 0.62M 0.77M 0.89M 0.95M
Net debt -1.27M - -2.73M -2.16M -2.80M
Short term debt 0.16M - - - -
Short long term debt total 0.20M - - - -
Other stockholder equity - - -0.00M -0.23M 0.07M
Total current assets 3.59M 1.54M 4.03M 3.47M 4.39M
Net tangible assets - - - 2.54M 3.40M
Net receivables 1.43M 0.02M 0.54M 0.51M 0.88M
Inventory 0.46M 0.54M 0.49M 0.56M 0.50M
Accounts payable 0.82M 0.39M 0.65M 0.80M 0.81M
Accumulated other comprehensive income -0.17M - -0.10M -0.23M 0.07M
Non current assets total 0.19M 0.31M 0.00M 0.00M 0.00M
Capital lease obligations - 0.32M - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 0.00M - -0.05M -0.00M
Change to liabilities - - - -0.01M 0.35M
Total cashflows from investing activities - - - -0.05M -0.00M
Net borrowings - -0.08M 0.00M - -
Total cash from financing activities 3.52M -0.08M 2.58M 1.55M 1.55M
Change to operating activities - - - 0.19M -0.17M
Net income -2.27M -2.24M -2.05M -2.40M -7.89M
Change in cash 1.07M -2.36M 0.57M -0.64M -2.46M
Begin period cash flow 0.40M 2.73M 2.16M 2.80M 5.26M
End period cash flow 1.47M 0.37M 2.73M 2.16M 2.80M
Total cash from operating activities -2.49M -2.29M -2.03M -2.19M -2.53M
Issuance of capital stock - - 2.65M 1.61M -
Depreciation 0.14M 0.10M - - 0.43M
Other cashflows from investing activities - - -0.00M - -
Change to inventory 0.09M -0.05M 0.07M -0.07M 0.24M
Change to account receivables -1.00M 0.03M 0.00M 0.11M -0.28M
Sale purchase of stock - - -0.07M -0.07M -
Other cashflows from financing activities -0.12M - 2.58M 1.55M -0.00M
Change to netincome - - - -0.01M 4.62M
Capital expenditures 0.00M 0.00M 0.00M 0.05M 0.00M
Change in working capital -0.45M -0.04M -0.09M 0.04M -0.04M
Stock based compensation - - 0.09M 0.05M 0.14M
Other non cash items 0.09M -0.11M 0.11M 0.11M 4.93M
Free cash flow -2.49M -2.29M -2.03M -2.24M -2.53M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
TRU
Truscreen Group Ltd		 -0.00
12.50%		 0.01 - - 3.34 4.37 3.20 -2.56
COH
Cochlear Ltd		 2.26
1.50%		 152.98 68.64 27.40 4.30 5.34 3.97 28.09
IMR
Imricor Medical Systems Inc		 0.06
4.72%		 1.33 - - 36401.21 17.45 4019.33 -2.60
AVR
Anteris Technologies Global Corp		 0.50
5.88%		 9.00 - - 356.02 2.19 130.34 -5.20
AVH
Avita Medical Inc		 -0.11
2.13%		 5.06 - 9.97 9.59 7.17 6.76 15.37

Profile*

Truscreen Group Ltd

TruScreen Group Limited, together with its subsidiaries, develops, manufacture, and sale of cancer detection devices and systems in Mexico, China, Central Asia, Vietnam, Zimbabwe, Indonesia, India, and the Middle East/North Africa. It offers TruScreen cervical cancer screening device, a medical device for identifying and detecting the presence of precancerous and cancerous tissue on the cervix in real time. The company was formerly known as TruScreen Limited and changed its name to TruScreen Group Limited in August 2020. TruScreen Group Limited was incorporated in 2013 and is headquartered in Auckland, New Zealand.

Equitable House, Auckland, New Zealand, 1010

61 2 8999 3896

https://www.truscreen.com

Name Title Year Born
Mr. Guy Adrian Robertson B.Com., B.Comm(Hons.), C.A., CA, MAICD CFO & Company Sec. 1954
Mr. Edmond Capcelea Chief Technology Officer NA
Dr. Beata Niechoda Edling Chief Exec. Officer NA
Dr. . Phunc Head of Cancer Department NA
Dr. . Chuong Head of R&D and Training Department NA
Dr. . Thuy Head of High Service Gynaecology Examination NA
Dr. Beata Niechoda Edling Chief Executive Officer NA
Dr. Beata Niechoda Edling Chief Executive Officer NA
Dr. Beata Niechoda Edling Chief Executive Officer NA
Mr. Guy Adrian Robertson B.Com., B.Comm(Hons.), CA, MAICD CFO & Company Secretary 1953

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…